Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: statussyndromehormonaltherapyartery
  Phrases that lowered it: the effecteffect ofindexbody massbmi
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports with a death: 8.1% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 67.4% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 375765 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 40 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant NCT02523898 · started 2015 · scored riskier than 15% of active trials terminated
• Chiglitazar/Metformin in Non-obese Women With PCOS NCT06125587 · started 2023 · scored riskier than 11% of active trials completed
• L-carnitine and Metformin in Obese PCOS Women. NCT03108963 · started 2017 · scored riskier than 5% of active trials completed
• Comparing the Effects of Oral Contraceptive Pills Versus Metformin NCT03229057 · started 2018 · scored riskier than 15% of active trials completed
• Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity NCT06140108 · started 2023 · scored riskier than 16% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.